On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee meets to decide whether seven peptides should be eligible for compounding. If you use BPC-157, TB-500, or any of the others on the list, this meeting affects whether you can legally obtain them. Here is what is actually being decided, what it is not, and what it means for you.
The FDA's Pharmacy Compounding Advisory Committee — PCAC — advises the agency on which substances belong on what is called the 503A Bulks List. That list governs which raw substances a compounding pharmacy may legally use to prepare a medication for an individual patient.
This matters because most peptides are not FDA-approved drugs. They reach patients through compounding pharmacies. If a substance is not eligible for compounding, there is no lawful route to obtain it for human use.
The meeting is scheduled for July 23 and 24, 2026 at the FDA's White Oak Campus in Silver Spring, Maryland, with teleconference access. It is a public meeting, held under docket FDA-2025-N-6895, published in the Federal Register on April 16, 2026.
Seven peptides are under consideration across the two days. The July 23 session covers four:
The remaining three under review are Emideltide (DSIP), Semax, and Epitalon. A further set of peptides is expected to be considered at a subsequent PCAC meeting before the end of February 2027.
If those names look familiar, it is because several are among the most discussed peptides in wellness circles. BPC-157 and TB-500 in particular have large followings built substantially on animal research and anecdote rather than human trials.
For each substance, PCAC evaluates three questions:
The committee then recommends inclusion or exclusion. The FDA is not bound by that recommendation, though it generally carries substantial weight.
This is the single most misrepresented point in the category right now, and it is worth being blunt about.
Some sellers have framed these peptides being placed on a PCAC agenda — or being procedurally moved out of Category 2 — as evidence that the FDA is about to bless them, or has already quietly done so. That is not what is happening. Being scheduled for review means the FDA is asking whether a substance is safe and necessary enough to permit. That question has not been answered. The answer could be no.
The FDA has been explicit that removal of a substance from Category 2 does not, on its own, authorize compounding it.
If a vendor is currently using this meeting as a reason you should buy now, they are inverting what the meeting means. An open regulatory question is not a green light.
Broadly, three things can follow for any given peptide.
Recommended for the list. The substance becomes eligible for compounding at 503A pharmacies, with a clearer and more stable legal path. This would be the most permissive outcome and would likely expand legitimate access.
Recommended against. Compounding that substance for patients would not be permitted. Practically, this would mean the peptide becomes considerably harder to obtain through any lawful channel.
Deferred. The committee may conclude the evidence is insufficient to decide either way and seek more data. Given how thin the human trial literature is for several of these compounds, this is a realistic outcome.
We would rather tell you honestly that we do not know which way this goes than pretend to have inside knowledge. Anyone forecasting the result with confidence is guessing.
If you currently use one of these peptides, or are considering starting, a few practical points.
This is a public process, and patient input is part of it. Comments may be submitted through regulations.gov under docket FDA-2025-N-6895. The comment period closes July 22, 2026, the day before the meeting begins. Nominators of the substances under review are also invited to present in support of their nominations.
If a compounded peptide has been part of your care, your experience is legitimate input into whether a clinical need exists. That is one of the three questions the committee is weighing.
No. The FDA is evaluating whether seven specific peptides should be eligible for compounding. This is not a ban on peptides as a category, and it has no bearing on FDA-approved peptide medications such as GLP-1 receptor agonists or insulin, which are approved drugs and unaffected by this review.
BPC-157 is not currently an FDA-approved drug. The review will help determine whether compounding pharmacies may lawfully prepare it. An unfavorable outcome would make it harder to obtain legitimately, rather than changing its status overnight for individuals.
No. Semaglutide and tirzepatide are FDA-approved drugs and are not part of this review. If you are on an approved GLP-1, nothing here changes your treatment.
The committee meets July 23 and 24, 2026. PCAC issues recommendations, and the FDA then decides how to act on them, which can take additional time. A recommendation at the meeting is not the same as a final rule.
An additional set of peptides is expected to be reviewed at a PCAC meeting before the end of February 2027. This July meeting is one step in a longer process, not the conclusion of it.
If you are on a peptide protocol and unsure how this review affects you — or you are considering one and want to understand the actual evidence and the actual legal footing before you start — call Alpine Health & Wellness in Kalispell, MT at 406-361-7421. Our provider team will review what you are taking, tell you plainly where the evidence stands, and help you plan around whatever the FDA decides.
For background on how peptides work, see our guide to peptide therapy and what peptides actually do, or read more about the most commonly used peptides.
This article is for general educational purposes and does not constitute medical or legal advice. It does not establish a provider-patient relationship. Peptide therapy is not appropriate for everyone. Regulatory details reflect FDA announcements and docket information available as of July 2026 and are subject to change; consult FDA.gov and regulations.gov for the current status. Please consult a qualified healthcare provider about your individual circumstances before starting, stopping, or changing any therapy.
